BALA CYNWYD, PA / ACCESSWIRE / October 14, 2020 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions. If you own shares of any of the below-referenced stocks and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, or calling toll free 877-534-2590. There is no cost or financial obligation to you.
MyoKardia, Inc. (NASDAQ:MYOK)
Under the terms of the agreement, MyoKardia stockholders will receive $225.00 in cash per MyoKardia share in the transaction. The investigation concerns whether the MyoKardia Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether BMY is paying too little for the Company. MyoKardia's lead product mavacamten, an experimental drug that treats obstructive hypertrophic cardiomyopathy, is already through Phase 3 testing programs and BMY's CEO has stated it "can be a multi-billion dollar asset."
Additional information can be found at https://www.brodskysmith.com/cases/myokardia-inc-nasdaq-myok/, or call 877-534-2590. No cost or obligation to you.
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)
Under the terms of the agreement, AMAG shareholders will receive only $13.75 for each share of AMAG they own. The investigation concerns whether the AMAG Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Covis is paying too little for the Company. For example, the deal consideration is below the Company's 52-week high.
Additional information can be found at https://www.brodskysmith.com/cases/amag-pharmaceuticals-inc-nasdaq-amag/, or call 877-534-2590. No cost or obligation to you.
Eidos Therapeutics, Inc. (NASDAQ:EIDX)
Under the terms of the agreement, Edios stockholders will have the right to receive in the transaction, at their election, either 1.85 shares of BridgeBio common stock or $73.26 in cash per Eidos share in the transaction, up to an aggregate maximum of $175 million of cash. The investigation concerns whether the Edios Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether BridgBio is paying too little for the Company. For example, at least one wall street analyst has set a $80.00 price target for Edios shares.
Additional information can be found at https://www.brodskysmith.com/cases/eidos-therapeutics-inc-nasdaq-eidx/, or call 877-534-2590. No cost or obligation to you.
Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
SOURCE: Brodsky & Smith, LLC